✉news BusinessLabor first seen 10 h ago, last 56 min ago, peak #9

Antibody-drug conjugates regain momentum in oncology

Original: Vital Signs: ADCs strike back

FirstWord Pharma's latest Vital Signs briefing reports that antibody-drug conjugates, a class of targeted cancer therapies, are striking back in the oncology field. The piece highlights renewed commercial and clinical momentum for ADCs, a segment that had faced setbacks, though no further detail is available from the headline.

Why now: Renewed momentum for ADC cancer drugs is a hot topic among pharma industry watchers following recent clinical and commercial developments.

FirstWord Pharmaantibody-drug conjugates

Open on news →

Rank over time, top of the chart is #1. 8 snapshots from 10 h ago to 56 min ago.

Evidence

• Vital Signs: ADCs strike back · FirstWord Pharma

API: https://socialmediatrends-api.osmike.com/v1/trends/1186291